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Abstract: Cryptosporidium is a major cause of severe diarrhea-related disease in children in 
developing countries, but currently no vaccine or effective treatment exists for those who are most 
at risk of serious illness. This is partly due to the lack of in vitro culturing methods that are able to 
support the entire Cryptosporidium life cycle, which has led to research in Cryptosporidium biology 
lagging behind other protozoan parasites. In vivo models such as gnotobiotic piglets are complex, 
and standard in vitro culturing methods in transformed cell lines, such as HCT-8 cells, have not 
been able to fully support fertilization occurring in vitro. Additionally, the Cryptosporidium life cycle 
has also been reported to occur in the absence of host cells. Recently developed bioengineered 
intestinal models, however, have shown more promising results and are able to reproduce a whole 
cycle of infectivity in one model system. This review evaluates the recent advances in 
Cryptosporidium culturing techniques and proposes future directions for research that may build 
upon these successes. 
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1. Introduction 
Parasites of the Cryptosporidium genus are among the main pathogens causing severe diarrheal 
disease and death in young children in developing countries [1]. In otherwise healthy individuals, 
Cryptosporidium infection is typically mild and self-limiting, however, in immunocompromised, 
malnourished, or very young patients the infection can be severe or even fatal [2]. The majority of 
Cryptosporidium-related deaths occur in children under five years of age, accounting for 
approximately 48,000 deaths in 2016 internationally within this age bracket. In Australasia, high-
income North America, and high-income Asia-Pacific, there were no Cryptosporidium-related deaths 
in children under five years of age reported in 2016, whereas in the same year and age bracket, 
approximately 42,000 Cryptosporidium-related deaths occurred in sub-Saharan Africa. This highlights 
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the reality that low-income countries bear a disproportionate burden globally for cryptosporidiosis, 
and sub-Saharan Africa is by far the most severely affected. In children, the disease burden of 
cryptosporidiosis is not limited to the span of acute diarrheal illness, with even mild or asymptomatic 
infection being associated with long-term consequences such as persistent nutrient malabsorption 
and stunted growth, which can cause significant harm later in life [3]. 
In developed nations, the burden of human cryptosporidiosis is highest in patients with human 
immunodeficiency virus and acquired immunodeficiency disease, although this is improving as a 
result of highly active antiretroviral therapy [4]. Most outbreaks occur due to contamination of 
recreational swimming pools or contact with either infected cattle or infected children [2]. The largest 
Cryptosporidium outbreak reported occurred as a result of contamination of the public water supply 
in Milwaukee, Wisconsin in 1993 and was estimated to have infected 403,000 people, causing 54 
deaths and costing $96.2 million in medical costs and lost productivity [5–7]. Despite the global 
attention Cryptosporidium received as a result of this outbreak, cryptosporidiosis is still poorly 
controlled and continues to be under-diagnosed, with surveillance studies likely underestimating the 
true magnitude of outbreaks occurring in both developed and developing countries [2,8]. 
Of significance to global disease burden, there is currently no available vaccine for 
Cryptosporidium infection and very limited treatment options [9]. The drug nitazoxanide is the only 
pharmaceutical intervention approved by the US Food and Drug Administration to treat 
Cryptosporidium infection. However, it is only efficacious in immunocompetent patients, leaving 
those in most urgent need with no effective treatment [10]. In the absence of a vaccine or effective 
therapeutic, the best prevention methods against cryptosporidiosis are public health approaches such 
as basic personal hygiene, sanitation, and filtration or disinfection of the drinking water supply [2], 
highlighting a gap in the research sector in developing preventions and treatments. 
Most Cryptosporidium infections in humans are caused by two species: Cryptosporidium hominis 
and Cryptosporidium parvum [11]. In addition to the inability to genetically manipulate 
Cryptosporidium until recently, and the inaccessibility of good animal infection models (particularly 
for C. hominis), the lack of a reliable method of in vitro propagation of either of these species has been 
a major reason why pharmaceutical and vaccine development has lagged behind other enteric 
pathogens of similar clinical importance [8,12]. Out of the four pathogens identified as causing the 
majority of moderate-to-severe diarrhea in children under five years of age (rotavirus, 
Cryptosporidium, Shigella, and enterotoxigenic Escherichia coli producing heat stable toxin) [1], 
Cryptosporidium is the only pathogen without either an effective vaccine or treatment [13–15]. 
1.1. Cryptosporidiosis 
Transmission of Cryptosporidium mainly occurs via the fecal–oral route, most frequently through 
contact with an infected person or animal or as a result of ingesting contaminated food or water. 
There are subtle differences in the clinical presentation between C. hominis and C. parvum infection, 
with C. hominis being associated with more severe disease including non-gastrointestinal symptoms 
such as headache, fatigue, and joint pain, whereas C. parvum infection generally presents clinically as 
diarrhea only. Additionally, given that C. hominis and C. parvum have different host ranges, the risk 
factors for infection and modes of transmission are species-specific to an extent. The main reservoirs 
for C. parvum are animal species, while for C. hominis the most important reservoir is likely to be 
young children with asymptomatic infection [2]. 
The pathogenesis of cryptosporidiosis begins with parasite attachment and invasion of host 
enterocytes in the small intestinal lumen, which results in disruption of epithelial permeability, 
ablation of the brush border, and blunting of villi. Increased enterocyte turnover to replace damaged 
cells results in crypt hyperplasia. The loss of microvilli causes a reduction in the absorptive surface 
area and therefore reduces fluid and nutrient uptake which presents clinically as a high volume, 
watery diarrhea [16]. 
While cryptosporidiosis is predominantly a gastrointestinal disease, Cryptosporidium is able to 
complete its life cycle within the respiratory tract, causing respiratory cryptosporidiosis, which 
occurs mainly in immunocompromised patients [17–19]. Possible routes of infection include the 
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spread of Cryptosporidium from the gastrointestinal tract to the respiratory tract through either 
circulation or inhalation of gastrointestinal contents during emesis. Person-to-person transmission 
may also occur through coughing. Respiratory cryptosporidiosis is uncommon in humans and 
represents a minor contribution to the epidemiology of disease caused by Cryptosporidium [20]. 
1.2. Life Cycle 
Cryptosporidium has a complex life cycle comprising both asexual (merogony) and sexual 
(gametogony) phases (Figure 1). The sporulated oocyst is the infectious environmental stage of the 
Cryptosporidium life cycle that is ingested by the host. Oocysts are highly resistant to standard 
disinfection practices and can survive for over a week in recreational water even at chlorine 
concentrations (>1–3 ppm) recommended by Centers for Disease Control and Prevention for 
maintenance of recreational swimming pools [2]. 
 
Figure 1. Diagrammatic representation of the Cryptosporidium life cycle in the intestine. 
Excystation of the oocyst occurs in the intestine and is triggered by the temperature and pH 
conditions of the host’s gastrointestinal tract, resulting in the release of four motile sporozoites [21]. 
Sporozoites invade the host’s intestinal epithelial cells on the luminal surface, where they reside 
inside a parasitophorous vacuole which assumes an intracellular but extracytoplasmic position in the 
host cell. Formation of an attachment or feeder organelle is followed by the remainder of the asexual 
cycle, which includes development of trophozoites, meronts, and merozoites. Trophozoites undergo 
asexual proliferation by merogony to form meronts. Meronts develop four or eight nuclei, each 
incorporated into a merozoite, which are released from the parasitophorous vacuole once mature and 
later invade the surrounding host epithelial cells. These merozoites will either recycle as meronts and 
merozoites, or initiate the sexual cycle. During the latter, merozoites invade new host cells and either 
enlarge and develop into a uni-nucleate macrogamont or undergo cellular fission forming a multi-
nucleated microgamont containing up to 16 non-flagellated microgametes. Microgametes are 
released from ruptured microgamonts; they penetrate host cells containing macrogamonts and 
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subsequently fertilize the macrogamont forming a zygote. Productive fertilization fails to occur in 
vitro which is the main reason why in vitro propagation is inherently difficult [22]. In the host, the 
zygote undergoes meiosis, during which both thin-walled and thick-walled oocysts are formed, each 
containing four potentially infective sporozoites. Thin-walled oocysts remain within the host leading 
to autoinfection and persistent infections, and thick-walled oocysts are shed in the feces [23]. 
In a study by Hijjawi et al. [24], the presence of previously undescribed Cryptosporidium andersoni 
and C. parvum novel gamont-like extracellular stages were observed in in vitro cell culture. C. 
andersoni extracellular stages were also observed in cattle feces and were isolated using laser 
microdissection and subsequently sequenced and confirmed as C. andersoni [24]. These extracellular 
stages were described as gregarine-like due to their similarities to stages found in the life cycle of 
gregarines [25,26] and have been subsequently reported by Rosales et al. [27]. Despite being found in 
C. andersoni and C. parvum, which represent two very distinct lineages and most likely capture the 
range of phylogenetic diversity within the Cryptosporidium genus, the origin, significance, and fate of 
these stages in the Cryptosporidium life cycle and presence in broader Cryptosporidium spp. are unclear. 
Additionally, the current understanding of Cryptosporidium biology is incomplete, as Cryptosporidium 
was considered an obligate intracellular parasite until extracellular life cycle stages were observed 
and the ability for Cryptosporidium to complete its life cycle without host cells was reported [24,27,28]. 
Thus, there is detailed knowledge of the Cryptosporidium life cycle, but clear gaps in the basic 
understanding of this complex process. 
1.3. In Vitro and In Vivo Models of Cryptosporidium Infection 
In vivo models of Cryptosporidium infection have included neonatal calves, gnotobiotic piglets, 
and both immunodeficient and immunocompetent mice [29–31]. Neonatal calves experimentally 
infected with C. parvum are an effective animal model for human cryptosporidiosis, with the 
pathophysiology observed in calves being very similar to what is identified in humans [29]. 
Gnotobiotic piglets have been used to model infection with both C. hominis and C. parvum and, like 
humans, they are equally susceptible to both species [30]. However, their use is highly labor intensive 
and expensive, which limits the number of animals that are able to be used per experiment [30]. 
Immunocompetent mice are not susceptible to C. hominis or C. parvum infection, although neonatal 
and immunodeficient mice can be infected with C. parvum. Immunocompetent mice have been used 
to model infection with the natural mouse pathogen Cryptosporidium muris. However, C. muris is 
genetically distinct from both C. parvum and C. hominis and the gastric site of infection is different to 
the intestinal site of infection observed in human cryptosporidiosis [31]. A recent study was able to 
model Cryptosporidium infection using immunocompetent mice naturally infected with 
Cryptosporidium tyzzeri with both host and parasite amenable to genetic manipulation using a 
CRISPR/Cas9 based approach [32]. Using C. tyzzeri had several advantages over using C. muris, 
including the former’s genetic similarity to C. parvum and C. hominis and ability to cause similar 
pathology in mice to what is observed in cryptosporidiosis in humans. The use of reporter parasites 
expressing red fluorescent proteins mCherry and red-shifted luciferase has enabled precise 
quantification of parasite load as well as the ability to identify the location of infection in the 
immunocompetent mouse host accurately over time. The key host immune responses involved in 
parasite clearance were determined using a knockout-based approach in the mouse, which were 
identified to be interferon gamma (IFN-γ) and T cells [32]. Given that all models rely on 
immunocompromised or neonatal animals or animals that are naturally resistant to C. parvum and C. 
hominis infection, little is known about the adaptive immune responses required for lasting protection 
against Cryptosporidium infection. 
In vitro models of Cryptosporidium infection have included the use of transformed cell lines 
which have been reviewed in detail elsewhere [33,34]. Long-term culture (over 25 days) has been 
reported using the human ileocecal adenocarcinoma (HCT-8) cell line after pH modification, gamma 
irradiation of the cell monolayer, and sub-culturing. However, fertilization is still not observed 
consistently and therefore this model does not reflect the complete Cryptosporidium life cycle [35]. 
More recently, the human esophageal squamous cell carcinoma (COLO-680N) cell line has been 
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reported to support C. parvum infection and remain viable for eight weeks and was able to produce 
an oocyst yield of 1.2 × 107 oocysts after 60 days, indicating that this cell line may be a promising 
option for future research [36]. The discovery that Cryptosporidium can complete its life cycle outside 
of a cellular host further justifies the use of an in vitro model over in vivo models [28], on top of the 
relative ease of use and lower cost. 
2. Cell-Free Culture of Cryptosporidium 
Hijjawi et al. [28] were the first to report that C. parvum is able to complete its life cycle in vitro 
in the absence of host cells. This was the first major breakthrough in culturing Cryptosporidium since 
1984 when successful in vitro culture of Cryptosporidium was originally reported [37]. Axenic culture 
(consisting of just one species and entirely free of other contaminating organisms) of C. parvum was 
achieved by using a dual phase culturing system with a semi-solid layer of coagulated newborn calf 
serum underneath a suspension of purified oocysts in maintenance medium. Using this culturing 
method, fertilization was observed in vitro for the first time, and evidence of continuation of the 
Cryptosporidium life cycle was observed. Additionally, oocysts collected after 46 days of cell-free 
culture were infective to ARC/Swiss mice, demonstrating the in vitro production of infectious 
oocysts. Prior to that study, Cryptosporidium was considered an obligate intracellular parasite, thus 
the discovery that Cryptosporidium was able to complete its life cycle in the absence of host cells caused 
a paradigm shift in the understanding of the Cryptosporidium life cycle [28]. However, the findings of 
Hijjawi et al. [28] were initially controversial [38,39], with independent research groups either failing 
to establish Cryptosporidium growth in cell-free culture altogether or only being able to sustain growth 
for a short period of time [40,41]. In response to disputes of the legitimacy of the findings of Hijjawi 
et al. [28], an independent study used a combination of quantitative PCR and immunofluorescence 
to confirm that parasite multiplication was occurring when C. parvum was cultured in the absence of 
host cells [42]. These results were then validated by Hijjawi et al. [43], who additionally confirmed 
observations of Cryptosporidium life cycle stages using Cryptosporidium-specific antibody stains and 
fluorescent in situ hybridization probes. 
Due to difficulty visualizing Cryptosporidium life cycle stages in cell-free culture compared to 
when grown in the presence of host cells, a study evaluating different staining methods found that 
life cycle stages were more readily able to be visualized with the use of antibody stains specific to 
Cryptosporidium such as Sporo-Glo™, known to bind to sporozoites, trophozoites, meronts, and 
merozoites [44]. Cell-free culture has also been validated using scanning electron microscopy and 
gene expression studies, which showed that gene expression patterns in Cryptosporidium were similar 
when cultured with and without host cells, but occurred at a slower rate with the latter [45]. 
Successful axenic culture of Cryptosporidium has since been reported by independent research groups 
[46–50] and life cycle stages have also been identified in a host cell-free biofilm environment [51]. In 
the study by Aldeyarbi & Karanis [48], evidence of the sexual stages of C. parvum development and 
the production of both thin- and thick-walled oocysts in cell-free culture were reported using 
transmission electron microscopy. Comparison of Cryptosporidium growth, both with and without 
host cells, has suggested that the host cells may enhance Cryptosporidium growth in vitro through the 
proteins they secrete into the growth medium and not necessarily through their role as a site of 
infection, though this finding requires additional confirmation [49,50]. Cell-free culture of 
Cryptosporidium has also enabled other aspects of parasite biology to be studied, including 
morphological changes that occur in sporozoites after excystation [52], the discovery of small 
molecules that induce parasite transformation from sporozoite to trophozoite [49], and several ultra-
structural similarities to the Gregarines to be visualized [47]. The discovery that Cryptosporidium can 
be cultured without host cells has made an important contribution to the study of Cryptosporidium 
biology, though it remains controversial. To aid the study of host-parasite interactions and the 
pathophysiology of cryptosporidiosis, alternative culturing methods have gained momentum in 
recent years. 
3. Bioengineered Intestinal Models for Culturing Cryptosporidium 
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Over the last five years, most attempts to grow C. parvum throughout its life cycle and produce 
new oocysts in vitro have centered around the use of bioengineered intestinal models involving 
perfusion or co-culture of various cells [53–55], including both mouse and human-derived intestinal 
organoids [56,57]. The pioneering work using a three-dimensional intestinal model to investigate 
Cryptosporidium infection utilized HCT-8 cells cultured in a low-shear, microgravity environment. 
Under these conditions, the HCT-8 cells were able to organize into tissue-like structures, including 
the formation of an apical brush border, tight junctions, and basal lamina. They were able to use this 
culturing system to study aspects of the pathophysiology of human cryptosporidiosis and 
demonstrate that the parasite load increased significantly in the three-dimensional intestinal model 
compared to standard HCT-8 cell cultures, but were limited by the short duration of time in which 
C. parvum could be maintained and could not enable the completion of the life cycle [58]. Subsequent 
three-dimensional intestinal models have mimicked the in vivo morphology of intestinal epithelial 
cells to varying degrees and have enabled the completion of the C. parvum life cycle in vitro. However, 
each of these C. parvum culturing systems have their limitations. 
3.1. Perfusion Intestinal Models 
Hollow fiber technology was the first to build on the work of Alcantara Warren et al. [58] and 
utilize HCT-8 cells inside a three-dimensional culturing system, with the experiment taking place 
within a hollow cylindrical cartridge containing several hollow fibers that run through its length 
(Figure 2a). HCT-8 cells were cultured on the outer surface of each hollow fiber and were supplied 
with a growth medium optimized for host cell growth from within each hollow fiber. The host cell-
specific medium was formulated to be oxygen and nutrient-rich and reached the HCT-8 cells from 
the basal surface. A pump system enabled the host-cell specific medium to be continuously refreshed. 
The compartmentalization of host cell-specific medium opened the opportunity for a separate growth 
medium optimized for C. parvum growth to occupy the extra-capillary space. The C. parvum-specific 
growth medium was developed to mimic the conditions of the human intestinal lumen, in terms of 
nutrient and oxygen concentration and redox conditions. The separate control of the medium 
supplied to both host cells and C. parvum was hypothesized to be key to the success of this model, 
which reported production of approximately 108 oocysts per mL per day and continuous culture of 
C. parvum for over six months. The oocysts produced in vitro were infectious to two different types 
of immunodeficient laboratory mice, with oocyst shedding at a volume similar to infection initiated 
by commercially acquired oocysts. This system was an exciting advancement in Cryptosporidium 
biology, providing a source of fully infectious oocysts for downstream in vitro and in vivo studies 
[53]. 
Limitations of the hollow fiber technology for the culture of C. parvum include the requirement 
for expensive and specialized equipment. This approach relies on transformed cell lines rather than 
primary cells and despite the practical advantages of using transformed cell lines—including lower 
cost, higher reproducibility, and ease of use—it has been argued that transformed cell lines cannot 
completely capture the host-parasite interactions that occur in vivo [55–57]. Additionally, the 
cartridge needs to be disassembled to access the cells growing on the hollow fiber surface for the 
application of basic imaging techniques, meaning that it cannot be used to study individual stages of 
the C. parvum life cycle or host-parasite interactions over time [53]. Furthermore, high-volume 
production of infectious oocysts in vitro using this system has yet to be replicated by other 
laboratories. 
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Figure 2. Summary diagram of the main three-dimensional intestinal models described in this review. 
(a) Cross-section of a hollow fiber cartridge described in Morada et al. [53] with hollow fibers 
containing host cell-specific medium in lime green, intestinal epithelial cells on the surfaces of each 
hollow fiber shown in peach and C. parvum-specific medium in the extra-capillary space shown in 
purple. (b) Cross-section of the silk protein scaffold model described in DeCicco RePass et al. [54] 
indicating the silk protein bulk space in blue, fibroblasts in the bulk space in orange, enterocytes and 
goblet cells on the luminal surface in peach and lime green respectively, and growth medium in the 
lumen in purple. (c) Mouse colon explant described in Baydoun et al. [55] maintained under air-liquid 
interface culturing conditions with the explant layer shown in peach and growth medium shown in 
orange. (d) Small intestine organoid described in Heo et al. [56] showing the organoid cultivated in a 
Matrigel layer indicated in orange and a layer of growth medium shown in peach. (e) Stem cell 
derived air-liquid interface culture described in Wilke et al. [57] showing growth medium in peach, 
fibroblast, and Matrigel layers in orange and each intestinal epithelial cell type in different colors. (f) 
Gut-on-a-chip described in Kim et al. [59] indicating PDMS layers in blue, vacuum chambers in 
purple, basal, and apical chambers divided by a semi-permeable membrane with growth medium 
shown in orange and a Caco-2 monolayer on the apical surface of the membrane shown in peach. 
3.2. Models Based on Co-Culture 
A smaller-scale three-dimensional intestinal model was bioengineered using silk protein 
scaffolds that supported the co-culture of human epithelial colorectal adenocarcinoma (Caco-2) cells 
and mucous-secreting goblet cells (HT29-MTX). This intestinal model was fabricated using a viscous 
silk protein solution poured into a cylindrical polydimethylsiloxane (PDMS) mold and fashioned into 
a porous bulk space with a hollow lumen (Figure 2b). Caco-2 cells and HT29-MTX cells were cultured 
onto the luminal surface, and primary human intestinal myofibroblasts were injected into the bulk 
space. The myofibroblasts from the bulk space secreted cytokines and growth factors that promoted 
the expansion and differentiation of the cells cultured on the luminal surface. As a result, the Caco-2 
cells differentiated into enterocyte-like cells containing brush borders and tight junctions and 
performed some of the functions observed in vivo, such as the production of alkaline phosphatase 
and sucrose isomaltase secretion. C. parvum infection was supported in this model for 15 days, during 
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which time the parasite load was stable. Some aspects of the pathophysiology of cryptosporidiosis, 
such as distortion and loss of microvilli, were also observed. The luminal contents of the intestinal 
model were also able to be passaged three times to fresh intestinal models and re-establish infection 
[54]. This culture system was only able to produce small numbers of oocysts in vitro, and did not 
demonstrate that the oocysts produced in vitro can establish infection in vivo, which the hollow fiber 
technology was able to achieve [53]. However, this model does show that the co-culture of Caco-2 
cells, HT29-MTX cells and primary human intestinal myofibroblasts can reproduce many aspects of 
the in vivo structure and function of human intestinal epithelial cells, and can serve as a model to 
study at least some aspects of the C. parvum multiplication, host-parasite interactions and the 
pathophysiology of cryptosporidiosis. 
3.3. Models Based on Primary or Stem Cell-Derived Cultures 
A recent study utilized colon explants from adult mice with severe combined immunodeficiency 
disease in a C. parvum culturing system (Figure 2c), building on the works of Castellanos-Gonzalez 
et al. [60] who were the first to use primary intestinal epithelial cells for this purpose. The three-
dimensional structure of the intestinal epithelial layer of the colon explants were able to be preserved 
for 35 days, including the presence of microvilli, villi-like, and crypt-like structures, connective tissue 
with collagen, fibroblasts, and smooth muscle cells. This model was able to support C. parvum 
infection for 27 days if the initial inoculum was very low (25 oocysts per explant) [55]. While this 
model may not be useful for the production of large amounts of infectious oocysts, its ability to 
support infection of a very low number of oocysts makes it an accurate representation of what occurs 
in vivo during C. parvum infection, which is often initiated by a very small inoculum. This quality 
also indicates that this technology may be a promising option to be adapted as a highly sensitive 
detection assay for C. parvum. The use of primary cells in this culturing system allowed for more 
relevant analysis of host-parasite interactions, including the identification of lesions indicative of 
intraepithelial neoplasia as a result of Cryptosporidium infection, which had not been explored in C. 
parvum culturing systems described prior to that study. 
Organoids are stem cell-derived, three-dimensional clusters of cells that resemble the in vivo 
structure and function of organs. Human intestinal organoids can originate from human biopsies or 
induced pluripotent stem cells and can faithfully reproduce the structure of intestinal epithelium 
[61,62]. The first study to utilize an organoid-based culturing system for the study of C. parvum 
biology used human biopsy-derived small intestine and lung organoids, which were able to support 
C. parvum growth throughout both the asexual and sexual stages of its life cycle (Figure 2d). 
Additionally, oocysts could be passaged within organoids for up to 28 days. C. parvum infection was 
most efficient in small intestine organoids in comparison to the lung organoids, and mainly infected 
differentiated enterocytes. New oocysts were produced in vitro, and these were able to produce in 
vivo infection in neonatal mice. The type I interferon pathway was upregulated in both lung and 
small intestine organoids 72 h post-infection with C. parvum, mirroring the host defenses observed in 
human cryptosporidiosis. This model was unable to produce large numbers of oocysts but was the 
first study to successfully utilize stem cell-derived organoids for the study of C. parvum and provided 
the only available model to study the pathophysiology of both respiratory and gastrointestinal 
cryptosporidiosis in humans [56]. 
A recent study using a mouse ileum stem cell-derived culture propagated under air-liquid 
interface conditions supported C. parvum growth throughout its entire life cycle for over 20 days 
while also producing between 100 and 1000 oocysts per day [57]. Air-liquid interface conditions 
allowed for the supply of medium to the culture from the basal surface, with the apical surface of the 
cells exposed to air (Figure 2e). This study utilized a complex experimental design, including the 
establishment of a mouse fibroblast cell monolayer on a Matrigel coated porous membrane, on top 
of which the stem cells were cultured. After establishing air-liquid interface culturing conditions, the 
stem cells differentiated into enterocytes with brush borders and tight junctions and mucous 
secreting goblet cells over the following two weeks. Following C. parvum infection of the 
differentiated monolayer, parasite load (as measured by qPCR) increased for 20 days to a 100-fold 
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increase from the initial inoculum. Transcriptomic analysis of the monolayer grown under air-liquid 
interface conditions compared to non-air-liquid interface conditions revealed that a number of cell 
cycle regulation and metabolic pathways were upregulated in cells grown under air-liquid interface 
conditions [57]. This study also found that secretory cell expression was not required for robust C. 
parvum growth in vitro after a cell monolayer derived from an Atoh1 knockout mouse (therefore not 
expressing transcription factor Atoh1 required for intestinal epithelial cells to differentiate into 
Paneth, goblet, and enteroendocrine cells) also supported C. parvum infection [57,63]. Oocysts 
produced in vitro were infectious and able to establish C. parvum infection in highly susceptible IFN-
γ receptor deficient mice and re-establish infection in a fresh air-liquid interface monolayer. 
The main factor associated with the large output of infectious oocysts in an in vitro culture 
system appears to be centered on the adequate supply of oxygen and nutrients to the host cells, 
whether these are primary intestinal epithelial cells or a transformed cell line. Both Morada et al. [53] 
and Wilke et al. [57] supplied medium to host cells from the basal surface upwards, and utilized 
either an oxygen-rich medium or an experimental set-up that allowed host cells to be exposed to air. 
Wilke et al. [57] argued that shifting host cell metabolism to favor oxidative phosphorylation over 
glycolysis may possibly have an important role in supporting robust growth of C. parvum. Other 
factors such as a low oxygen luminal environment to promote C. parvum growth, the presence of 
differentiated intestinal secretory cells and the use of primary intestinal epithelial cells over 
transformed cells appeared less important when the goal was to produce large quantities of 
functionally relevant C. parvum oocysts. 
The maximum amount of time that any of the described culturing systems have been able to 
support continuous C. parvum growth is 40–45 days with passaging, with the exception of hollow 
fiber technology [54,57]. If using a three-dimensional model to study host-parasite interactions and 
the pathophysiology of cryptosporidiosis, the presence of differentiated enterocytes and the ability 
to apply imaging techniques to the culturing system is of the utmost importance. All of the three-
dimensional culturing systems were able to reproduce the structural characteristics of enterocytes 
such as tight junctions and brush borders, but most either lack the ability to produce large numbers 
of infectious oocysts or visualize host-parasite interactions over time. A summary of the current in 
vitro culturing methods for Cryptosporidium is shown in Table 1. 
Table 1. Summary table of the advantages and limitations of current in vitro culturing methods of 
C. parvum 













HCT-8 cell lines  No 25 days Partially No 
Hijjawi et al. 
[35] 
Cell-free culture Yes 46 days No Partially 




Yes <180 days Partially Yes 




Yes 15 days Partially No 
DeCicco 
RePass et al. 
[54] 
Colon explants Yes 27 days Yes No 
Baydoun et al. 
[55] 
Lung and small 
intestine 
organoids 
Yes 28 days Yes No Heo et al. [56] 
Stem cell-derived 
cultures 
Yes <20 days Yes No 
Wilke et al. 
[57] 
4. Organ-on-a-chip Technology 
While most groups currently working towards continuous culture of Cryptosporidium are using 
bioengineered intestinal models, there are currently no published reports utilizing microfluidic 
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organ-on-a-chip technology for this purpose. Organ-on-a-chip technology aims to reproduce the key 
features of the three-dimensional structure and function of specific tissues in the body on a 
miniaturized scale in vitro. The use of microfluidics enables fine control of the cellular 
microenvironment, including control of fluid flow through the device, shear stress on the cells, and 
input of mechanical stimuli [64]. Mimicking the mechanical cues that cells experience in vivo to cells 
cultured in vitro has been demonstrated to promote cell differentiation and formation of the three-
dimensional architecture of in vivo tissues [65]. A microfluidic organ-on-a-chip device aiming to 
mimic the human intestine may be able to provide the ideal conditions to enable Cryptosporidium 
growth in vitro and is small-scale and affordable enough to be used in a variety of applications in the 
study of Cryptosporidium biology. 
The first in vitro microfluidic devices aiming to reproduce the three-dimensional structure of the 
intestinal epithelium were designed for pharmaceutical testing. Common features integrated into the 
design of the devices included two-compartment culture chambers fabricated from PDMS, with the 
basolateral and apical chambers divided by a flat, semi-permeable membrane. These microfluidic 
devices accommodated either Caco-2 cell monolayer formation or Caco-2/HT29-MTX co-cultures, the 
latter of which enabled mucous layer development. Advantages of using microfluidic devices over 
standard cell culture included the ability to establish more physiologically relevant culturing 
conditions, such as the application of fluid flow and shear stress on cells, which in turn increased the 
capacity for long term maintenance of the cell monolayer. More practical advantages included the 
lower cell and reagent requirements, sparing of laboratory animals and the potential for high 
throughput experiments [66–68]. While the potential for these microfluidic devices to overcome some 
of the obstacles associated with standard cell culture was evident, these earlier studies often struggled 
with reproducibility of results, indicating that further refinement of the device design was necessary. 
A subsequent study constructed a human gut-on-a-chip microfluidic device that enabled Caco-
2 cells to differentiate into all four of the major intestinal epithelial cell lineages (enterocyte, mucous-
secretory, enteroendocrine, and Paneth cells) and spontaneously form villi-like structures. The 
overall design of the microfluidic device was similar to its predecessors but incorporated additional 
lateral vacuum chambers that could induce peristalsis-like contractions of the semi-permeable 
membrane (Figure 2f). The apical surface of the membrane was coated with an extracellular matrix 
solution containing rat collagen and Matrigel before Caco-2 cells were cultured on top. Within this 
gut-on-a-chip environment, Caco-2 cells differentiated after three days of culture compared to 21 
days of static culture. The cells also adopted a columnar shape. Scanning electron microscopy showed 
that the villi-like structures were lined with cells containing apical microvilli forming brush borders 
with tight junctions between each cell. The majority of the villi were composed of enterocytes, with a 
small number of goblet cells and Paneth cells, which was consistent with the intestinal epithelial cell 
population observed in vivo. The crypt-villus units observed in this gut-on-a-chip microfluidic model 
were able to mimic the in vivo situation where rapidly proliferating cells are found in the crypt 
regions and differentiate as they migrate upwards towards the villus tip [59,65]. The spontaneous 
formation of villi-like structures removed the requirement for custom fabricated porous membranes 
that reproduced the surface structure of villi seen in a previous microfluidic device [69]. As expected, 
under static culturing conditions, Caco-2 cells grew flat and had a squamous shape. 
The unique features displayed by the Caco-2 cell monolayers cultured within this microfluidic 
device were mainly attributed to a combination of mimicking intraluminal fluid flow and peristalsis-
like motions. Interestingly, removing peristalsis-like contractions from the gut-on-a-chip did not 
result in significant loss of the columnar cell shape, which indicates that the fluid flow and resulting 
application of shear stress on the cells is the key factor for the maintenance of physiological cell 
morphology [59,65]. The key role of the microfluidic shear stress on Caco-2 cell monolayers was 
recently illustrated and systematically investigated, stressing the need to finely control the 
microfluidic culture conditions [70]. 
Based on the findings from that study, it was established that the local mechanical 
microenvironment drive the differentiation of Caco-2 cells, producing a highly physiologically 
relevant intestinal model that even demonstrated the ability to accommodate commensal bacterial 
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infection [65]. While it is clear that human gut-on-a-chip models can accurately reproduce the in vivo 
structure and function of the human intestinal epithelium, the question is raised as to whether this 
technology is able to support the growth of an enteric pathogen that is difficult to cultivate under 
standard approaches. A recent study successfully used the microfluidic device described by Kim et 
al. [59] to support the growth of Shigella flexneri and enhance bacterial invasion by 10,000-fold when 
compared to a Caco-2 cell monolayer cultured statically. The results of this study indicate that the 
combination of peristaltic motions, application of physiological fluid flow rates and, most 
importantly, the three-dimensional organization of Caco-2 cells into villus- and crypt-like structures, 
were mandatory for S. flexneri to efficiently infect the Caco-2 cell monolayer. Additionally, this gut-
on-a-chip model was highly sensitive to S. flexneri infection with a bacterial load of 100 being 
sufficient to produce robust infection [71]. The results of this study provide a promising 
methodological justification for using organ-on-a-chip technology to overcome the current obstacles 
in culturing Cryptosporidium. 
While most studies have utilized the Caco-2 cell line in organ-on-a-chip devices aiming to mimic 
the in vivo intestine, several studies used primary intestinal epithelial cells. The first primary cell 
microfluidic culture study used intestinal tissue slices from male Wistar rats. The slices were grown 
inside a microfluidic device that was designed to enable the tissue slice to be suspended in growth 
medium. Other features of this device included the control of fluid flow rate with syringe pumps, 
polycarbonate filters at the entrance and exit of the tissue chamber to ensure even distribution of 
medium and PDMS membranes forming gas permeable barriers allowing oxygen and carbon dioxide 
from the environment to enter the growth medium. Despite the controlled fluid flow enabling the 
growth medium to be continuously refreshed without damaging the intestinal tissue, morphological 
characteristics of healthy intestinal epithelial tissue such as the presence of villi were lost after only 
three hours of culture [72]. A subsequent study utilized primary intestinal epithelial cells in a 
multiorgan-on-a-chip device through the use of cells from the ileum of a human donor. The device 
described in that study was designed for pharmaceutical testing and contained endothelial cells 
cultured on the microchannel walls to mimic the human vasculature, peristaltic pumps integrated 
into the chip to control fluid flow, and a human liver mimic in addition to the intestinal model. 
Differentiation was induced over 14 days outside the microfluidic device using air-liquid interface 
culturing conditions, following which the primary cells were then viable within the microfluidic 
device for an additional 14 days [73]. 
More recently, studies have been integrating human intestinal organoids into organ-on-a-chip 
devices to mimic the in vivo human intestine. In one study, induced pluripotent stem cells were 
differentiated into human intestinal organoids and incorporated into a microfluidic device 
comprising a dual chamber system separated by a Matrigel coated semi-permeable membrane. The 
organoid formed a confluent monolayer after 72 h. It was found that the incorporation of fluid flow 
into the microfluidic device enhanced the three-dimensional structure of the organoid when 
compared to static culturing conditions, and after 14 days, villi formation was observed. All four 
major intestinal epithelial lineages were present. A gene expression study showed that when 
incubated with IFN-γ, a number of genes associated with inflammatory bowel disease were 
upregulated, which was not the case in the same device containing Caco-2 cells. This provided 
evidence that a human intestinal organoid-based model can more faithfully reproduce in vivo 
responses compared to a Caco-2-based model [74]. 
Another study used human biopsy-derived intestinal organoids in the context of an organ-on-
a-chip microfluidic device to mimic the human small intestine. This experimental set-up used the 
standard PDMS-based dual chamber approach separated by an extracellular matrix-coated semi-
permeable membrane and additionally cultured endothelial cells on the luminal surfaces of the 
basolateral chamber to imitate human vasculature [75]. The lateral vacuum chambers and syringe 
pumps described in Kim et al. [59] were incorporated to initiate peristalsis-like contractions of the 
semi-permeable membrane and fluid flow respectively. Organoids derived from the duodenal region 
of the small intestine were expanded and cultured in the apical chamber, where they formed villi-
like structures over 8–12 days. Confocal microscopy confirmed brush border and tight junction 
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formation. A transcriptomic approach was used to compare gene expression patterns between the 
gut-on-a-chip, organoid cultured under static conditions and the organoid-based intestine-on-a-chip 
described by Kasendra et al. [75] and showed that the transcriptome from the organoid-based 
intestine-on-a-chip was more similar to a human in vivo intestinal transcriptome than the intestinal 
organoid or the Caco-2 cell based gut-on-a-chip. 
A combination of organ-on-a-chip and organoid technology as described above may be able to 
overcome the current obstacles in continuous culture of Cryptosporidium. Additionally, these systems 
are small scale, inexpensive, and reproducible enough to be used in a variety of applications (Table 
1). Utilizing stem cell-derived cultures will build upon the works of Heo et al. [56] and Wilke et al. 
[57] who were able to use this approach to further the knowledge of Cryptosporidium biology and 
study the pathophysiology of cryptosporidiosis, though are still limited by the practical difficulties 
in recovering oocysts for reinfection in the case of organoids and relatively low parasite amplification 
in both studies [56,57]. The integration of organ-on-a-chip technology will make this approach more 
accessible to both researchers and industry and to facilitate high-throughput experiments which will 
aid detection assays, potentially for public health monitoring, and infectious assays, that can be used 
for screening for potential drug targets. 
5. Conclusions and Future Directions 
The recent successes in the long-term culturing of C. parvum using three-dimensional intestinal 
models and both mouse and human-derived intestinal organoids have laid the foundation for future 
expansions in the study of Cryptosporidium biology and elucidation of host-parasite interactions, that 
at present are not well understood. Further advances in these contemporary culturing techniques 
based on organ-on-a-chip technology may enable high-throughput discovery of drug targets in 
addition to forming the basis for detection and viability assays that are paramount to outbreak 
prevention. The lack of the ability to easily culture both C. hominis and C. parvum has been a major 
barrier in advancing the current knowledge of Cryptosporidium biology and overcoming current 
obstacles in reducing the global burden of cryptosporidiosis. By accurately reproducing the structure 
and function of the human intestinal epithelia, this new culturing technology may be able to address 
this issue for both C. hominis and C. parvum, providing a promising solution to a major barrier in 
Cryptosporidium research. 
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